))
Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs
Manage episode 468540698 series 3645695
Content provided by Joe Brunetto. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joe Brunetto or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
CEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm
9 episodes
Share
